OncoMatch/Clinical Trials/NCT07795437
GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma
Official title: Clinical Study of Glypican-3 (GPC3)-Targeted Novel Probe 18F-X12 for the Diagnosis of Hepatocellular Carcinoma (HCC)
Is NCT07795437 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies non-drug interventions for hepatocellular carcinoma (hcc).
This is a diagnostic study. This clinical trial aims to evaluate the diagnostic performance and safety of the novel radiotracer 18F-X12 in patients with hepatocellular carcinoma (HCC), and to provide evidence supporting a new approach for its early diagnosis, accurate staging and recurrence assessment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07795437 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages